The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision supportAnja Irmisch, Martina Haberecker, Michael Prummer et al.|Cancer Cell|2021Cited by 140
High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activitySohyon Lee, Berend Snijder, Tobias Weiß et al.|Nature Medicine|2024Cited by 68
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaKlara Kropivšek, Berend Snijder, Paul Kachel et al.|Nature Cancer|2023Cited by 42
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaRebekka Wegmann, Stefanie Engler, Ximena Bonilla et al.|Nature Communications|2024Cited by 25
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated MelanomaOssia M. Eichhoff, Mitchell P. Levesque, Corinne I. Stoffel et al.|Cancer Research|2023Cited by 24